Nykredit A S Buys Shares of 23,785 Labcorp Holdings Inc. $LH

Key Points

• Nykredit A/S acquired 23,785 Labcorp shares during the second quarter, worth approximately $6.66 million. Institutional investors and hedge funds collectively own 95.94% of Labcorp.
• Labcorp reported quarterly results above expectations, with EPS of $4.99 versus the $4.78 consensus and revenue of $3.73 billion. The company’s revenue increased 5.8% year over year and it reaffirmed fiscal 2026 EPS guidance of $18.10–$18.55.
• Analysts maintain a positive outlook, with a consensus “Moderate Buy” rating and an average price target of $337.73 versus the reported share price of $321.27. Labcorp also pays a quarterly dividend of $0.72, equivalent to a 0.9% annual yield.

Nykredit A S acquired a new stake in shares of Labcorp Holdings Inc. (NYSE:LH - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 23,785 shares of the medical research company's stock, valued at approximately $6,660,000.

Several other hedge funds also recently modified their holdings of LH. Hilton Head Capital Partners LLC acquired a new position in Labcorp during the fourth quarter valued at approximately $27,000. Allied Private Wealth LLC bought a new position in Labcorp during the second quarter valued at about $33,000. Cedar Mountain Advisors LLC boosted its stake in Labcorp by 786.7% during the first quarter. Cedar Mountain Advisors LLC now owns 133 shares of the medical research company's stock worth $35,000 after buying an additional 118 shares in the last quarter. SHP Wealth Management bought a new stake in Labcorp in the fourth quarter valued at about $40,000. Finally, Larson Financial Group LLC lifted its position in shares of Labcorp by 37.0% during the 4th quarter. Larson Financial Group LLC now owns 211 shares of the medical research company's stock worth $53,000 after buying an additional 57 shares during the period. Institutional investors and hedge funds own 95.94% of the company's stock.

Insider Activity

In other news, EVP Kathryn W. Kyle sold 92 shares of Labcorp stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total value of $26,329.48. Following the completion of the transaction, the executive vice president owned 3,904 shares of the company's stock, valued at $1,117,285.76. This trade represents a 2.30% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Adam H. Schechter sold 4,669 shares of the business's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $320.37, for a total transaction of $1,495,807.53. Following the transaction, the chief executive officer owned 102,565 shares in the company, valued at $32,858,749.05. This represents a 4.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 8,919 shares of company stock worth $2,826,593. Corporate insiders own 0.84% of the company's stock.

Labcorp Stock Up 0.2%

NYSE:LH opened at $321.27 on Tuesday. The stock has a 50-day simple moving average of $315.41 and a 200 day simple moving average of $283.41. Labcorp Holdings Inc. has a 52-week low of $244.52 and a 52-week high of $341.80. The company has a market cap of $26.05 billion, a PE ratio of 26.57, a PEG ratio of 1.82 and a beta of 0.88. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.53 and a current ratio of 1.80.

Labcorp (NYSE:LH - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The medical research company reported $4.99 earnings per share for the quarter, topping analysts' consensus estimates of $4.78 by $0.21. The firm had revenue of $3.73 billion during the quarter, compared to the consensus estimate of $3.71 billion. Labcorp had a return on equity of 16.74% and a net margin of 6.99%.The business's revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $4.35 EPS. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. On average, sell-side analysts expect that Labcorp Holdings Inc. will post 18.32 EPS for the current fiscal year.

Labcorp Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 28th were paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date was Friday, August 28th. Labcorp's dividend payout ratio (DPR) is currently 23.82%.

Wall Street Analyst Weigh In

A number of research firms recently commented on LH. Truist Financial increased their price target on Labcorp from $350.00 to $365.00 and gave the stock a "buy" rating in a research report on Monday. Mizuho set a $355.00 target price on Labcorp in a report on Monday, August 10th. Bank of America upped their price target on Labcorp from $300.00 to $320.00 and gave the company a "buy" rating in a research note on Monday, July 13th. Robert W. Baird set a $352.00 price objective on shares of Labcorp in a research note on Friday, July 31st. Finally, Wall Street Zen raised shares of Labcorp from a "hold" rating to a "buy" rating in a research report on Sunday, July 12th. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $337.73.

Labcorp Company Profile

Labcorp NYSE: LH, formerly Laboratory Corporation of America Holdings, is a global life sciences and laboratory services company headquartered in Burlington, North Carolina. The company provides diagnostic testing and related services to physicians, hospitals, health systems, employers, government agencies and consumers.

Its diagnostics business offers routine and specialty laboratory testing, including molecular, genetic, oncology, women's health, infectious disease and pathology services.

Want to see what other hedge funds are holding LH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Labcorp Holdings Inc. (NYSE:LH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.